Clinical Trials

140 enrolled

HER2 Negative Breast Cancer

NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

400 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06086704 2026-05-18

Study of 18F-FFNP Breast PET/MRI

53 enrolled

Breast Neoplasms

NCT06507618 2026-05-08

POWER II

354 enrolled

Breast Neoplasms

NCT05501704 2026-04-30

ETHAN - ET for Male BC

60 enrolled

Breast Neoplasms, Male

NCT04852887 2026-04-23

DEBRA

1,670 enrolled

Breast Neoplasms

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT05837455 2026-04-13

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

81 enrolled

Breast Neoplasms

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT05467891 2026-04-08

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT05524584 2026-03-11

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

20 enrolled

Breast Neoplasms

NCT03624244 2026-02-17

BFR-ESS

40 enrolled

Gynecologic

Endometrial Stromal Tumors

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

88 enrolled

Breast Neoplasms

NCT07190443 2025-09-29

AURA

290 enrolled

Breast Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

32 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT05190094 2025-05-07

ICRG0201

80 enrolled

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

NCT04985266 2024-12-05

TRAK-ER

1,100 enrolled

ER+ Breast Cancer

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Breast Neoplasms

NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Phase NA Recruiting

60 enrolled

HR Positive HER2 Negative Advanced Breast Cancer

NCT04666961 2022-04-22

HORNEO01

262 enrolled